Abstract
Introduction
Status epilepticus (SE) is a medical emergency requiring prompt treatment to try to limit mortality and improve outcome. So far, newer antiepileptic drugs (AED) have not assumed a noticeable role in the treatment of SE. This may be in part due to the lack of IV forms for the newer AEDs. The IV form of Levetiracetam (IV-LEV) has recently become available and has a potential role in the treatment of SE.
Methods and results
We report two cases of non-convulsive SE that responded favorably to IV-LEV. The first patient is an 83-year-old male with a history of complex partial seizure disorder who presented with impaired consciousness. The second patient is an 82-year-old male with history of old left middle cerebral artery ischemic infarction, who presented with confusion. Both patients were found to have a non-convulsive status epilepticus on electroencephalography (EEG) and treated with IV-LEV. In both cases, electrographic SE stopped with marked clinical improvement. Both patients tolerated the medication well and no significant side effects occurred.
Conclusion
IV-LEV may have a potential role in the treatment of non-convulsive status epileptics.
References
Patel NC, Landan IR, Levin J, Szaflarski J, Wilner AN. The use of levetiracetam in refractory status epilepticus. Seizure 2006;15(3):137–41.
Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol 2005;54(1):34–8.
Rupprecht S, Franke K, Fitzek S, Witte OW, Hagemann G. Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res 2006.
Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47(7):1128–35.
Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006;536(1–2):102–8.
Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284(2):474–9.
Dedeurwaerdere S, Vonck K, De Herdt V, et al. Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy. Acta Neurol Belg 2006;106(2):91–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Farooq, M.U., Naravetla, B., Majid, A. et al. IV levetiracetam in the management of non-convulsive status epilepticus. Neurocrit Care 7, 36–39 (2007). https://doi.org/10.1007/s12028-007-0022-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-007-0022-z